12.3 C
Innichen
July 1, 2022
Science and Medical

More Is Not Better in Metastatic CR Prostate Cancer – Medscape

More Is Not Better in Metastatic CR Prostate Cancer - Medscape thumbnail

CHICAGO More is not better when it comes to inhibition of the androgen receptor in men with metastatic castration-resistant prostate cancer (mCRPC), the Alliance study shows.
Indeed, treating patients with both enzalutamide (Xtandi, Astellas) and abiraterone…
Read More

Related posts

2 more cases of mumps confirmed at Elon University, bringing total to 3 – WXII12 Winston-Salem

Administrator

Measles Patient Who Visited L.A. CVS, Ralphs May Have Exposed Others: Health Officials – KTLA Los Angeles

Administrator

Opioid overdose deaths are down but the fight is far from over – WJLA

Administrator

Leave a Comment

* By using this form you agree with the storage and handling of your data by this website.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Privacy & Policy